Eli Lilly and Company Asset Resilience Ratio
Eli Lilly and Company asset resilience ratio. Eli Lilly and Company (LLY) has an Asset Resilience Ratio of 0.13% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LLY defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Eli Lilly and Company (1999–2025)
Asset resilience ratio of Eli Lilly and Company from 1999 to 2025. This chart shows how Eli Lilly and Company's Asset Resilience Ratio has changed over time. Read debt load of Eli Lilly and Company for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Eli Lilly and Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Eli Lilly and Company total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $146.00 Million | 0.13% |
| Total Liquid Assets | $146.00 Million | 0.13% |
Asset Resilience Insights
- Limited Liquidity: Eli Lilly and Company maintains only 0.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Eli Lilly and Company Industry Peers by Asset Resilience Ratio
Compare Eli Lilly and Company's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Cosmo Pharmaceuticals N.V
F:C43 |
Drug Manufacturers - General | 10.92% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 6.34% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
Eli Lilly and Company Asset Resilience Ratio by Year (1999–2025)
Eli Lilly and Company asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Eli Lilly and Company.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.56% | $7.37 Billion | $112.48 Billion | +2.21pp |
| 2024-12-31 | 4.35% | $3.42 Billion | $78.71 Billion | -0.23pp |
| 2023-12-31 | 4.57% | $2.93 Billion | $64.01 Billion | +0.10pp |
| 2022-12-31 | 4.47% | $2.21 Billion | $49.49 Billion | -3.54pp |
| 2021-12-31 | 8.01% | $3.91 Billion | $48.81 Billion | +0.11pp |
| 2020-12-31 | 7.89% | $3.68 Billion | $46.63 Billion | +1.69pp |
| 2019-12-31 | 6.21% | $2.44 Billion | $39.29 Billion | -10.67pp |
| 2018-12-31 | 16.87% | $7.41 Billion | $43.91 Billion | -0.99pp |
| 2017-12-31 | 17.86% | $8.03 Billion | $44.98 Billion | +2.30pp |
| 2016-12-31 | 15.56% | $6.04 Billion | $38.81 Billion | +13.35pp |
| 2015-12-31 | 2.21% | $785.40 Million | $35.57 Billion | -0.42pp |
| 2014-12-31 | 2.63% | $955.40 Million | $36.31 Billion | -1.81pp |
| 2013-12-31 | 4.45% | $1.57 Billion | $35.25 Billion | -0.40pp |
| 2012-12-31 | 4.84% | $1.67 Billion | $34.40 Billion | +1.95pp |
| 2011-12-31 | 2.90% | $974.60 Million | $33.66 Billion | +0.53pp |
| 2010-12-31 | 2.37% | $733.80 Million | $31.00 Billion | +2.24pp |
| 2009-12-31 | 0.13% | $34.70 Million | $27.46 Billion | -1.34pp |
| 2008-12-31 | 1.47% | $429.40 Million | $29.21 Billion | -4.54pp |
| 2007-12-31 | 6.01% | $1.61 Billion | $26.79 Billion | +2.45pp |
| 2006-12-31 | 3.56% | $781.70 Million | $21.96 Billion | -4.70pp |
| 2005-12-31 | 8.26% | $2.03 Billion | $24.58 Billion | -0.18pp |
| 2004-12-31 | 8.44% | $2.10 Billion | $24.87 Billion | +4.03pp |
| 2003-12-31 | 4.41% | $957.00 Million | $21.68 Billion | -4.56pp |
| 2002-12-31 | 8.97% | $1.71 Billion | $19.04 Billion | +2.71pp |
| 2001-12-31 | 6.26% | $1.03 Billion | $16.43 Billion | +2.83pp |
| 2000-12-31 | 3.43% | $503.30 Million | $14.69 Billion | +2.37pp |
| 1999-12-31 | 1.06% | $135.60 Million | $12.83 Billion | -- |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 7… Read more